Mercadon's second-quarter results: Total revenue of $10.9 billion K drug sold for $3.4 billion!
Time of Update: 2020-08-04
percent to $3.4 billion in the oncology business, driven by the continued strength of non-small cell lung cancer adaptation and the continued absorption of other indications, including assisted treatments for melanoma, kidney cell carcinoma
The third "A-H" company in the field of domestic CRO is about to be born.
Time of Update: 2020-07-30
existing businesses. in the industry's view, the Currenter Pharma in the A-share basis to choose to add code H shares, on the one hand, is conducive to increasing financing channels, on the other hand, CRO business also needs to move towards
syndrome are MSI-H/dMMR, what next step should be to test?
Time of Update: 2020-07-29
protein test results, screened 170 patients with MLH1 (-) bowel cancer, and finally included 109 patients who had tested the embryo system and had tumor tissue samples, and were tested for MLH1 methylation and BRAF mutation The researchers first
Consino was approved by the company's IPO, the first A-H vaccine stock was born!
Time of Update: 2020-07-29
Guide: Consinibolo Bio was listed on the Hong Kong Stock Exchange in March 2019 !----, and on July 15, the CSRC issued a number of IPO approvals for corporate companies, including Consino Bio Consinctbios was listed on the Hong Kong Stock
"Pharmaceutical headline Jun" K drug combination therapy treatment liver cancer u.S. market rejected.
Time of Update: 2020-07-23
Since July , the big infusion leading pharmaceutical companies continue to come to good news: Collum Pharmaceuticals has won Pfizer' s global super$2 billion variety of acetic tablets of the domestic imitation; Domestic brand potential can be expected.
Heavy! Mercado Keytruda approved by the U.S. FDA for the second "unlimited cancer" indications: high tumor mutation burden (TMB-H) solid tumor!
Time of Update: 2020-07-20
, June 18, 2020 /PRNewswire/ -- Merck and Co has announced that the U.S. Food and Drug Administration ( FDA ) has approved Keytruda (Corrida, generic name: pembrolizumab, Pabo) lizumab as a monodrug therapy for the treatment
FDA News . . . Paboli sepsal lightning was approved for first-line treatment of MSI-H/dMMR metastatic colorectal cancer.
Time of Update: 2020-07-18
On June 29, 2020, the FDA approved pembrolizumab (Pabolizumab) first-line treatment for non-removable or metastatic colorectal cancer (mCRC) for highly microsatellite instability/mismatch repair defects (MSI-H/dMMR). . The approval
Best CP! There is a new breakthrough in the treatment of advanced gastric cancer in the combination of "k drug and lunvalitini".
Time of Update: 2020-07-18
Gastric cancer is the second largest cancer in China, the incidence and death of nearly 50% of the world, 80% of gastric cancer patients at the time of diagnosis is already late, treatment has been very limited, 5 years survival rate of only about 15
first-line treatment of MSI-H/dMMR patients and will change treatment patterns.
Time of Update: 2020-07-18
, June 30, 2020 / bio-valley, -- Merck and Co recently announced that the U.S. Food and Drug Administration ( FDA ) has approved the anti-PD-1 therapy Keytruda (Corrida, generic name: pe Mbrolizumab, Paboli Zumab
AXA Pharma and Mercado cooperate to explore APG-115 joint K drug treatment for advanced solid tumors
Time of Update: 2020-07-15
AXA Pharma today announced a global clinical research partnership with Mercado, a company based in Kenneworth Merck, New Jersey, USA.
Asain Pharma and Mercado have reached a global clinical partnership to explore its APG-115 joint "K drug" treatment of advanced solid tumors.
Time of Update: 2020-07-13
Read: Asain Pharma and Mercado will share relevant research information through the Joint Development Committee. Axa Pharmaceuticals (6855. HK) announced on July 6 that it has established a global clinical research partnership with Mercado
FDA approves Keytruda as first-line therapy for MSI-H/ dMMR metastatic colorectal cancer
Time of Update: 2020-07-10
FDA today approved Keytruda (pembrolizumab) as a first-line treatment for patients with microsatellite instability (MSI-H) or mismatch edimen (dMMR) metastasis colorectal cancer .
Clin Gastroenterology H: Increased esophageal symptoms in obese patients due to increased esophageal acid exposure rather than movement disorders
Time of Update: 2020-07-10
Background and objective esophageal motor disorder (EMD) and pathological reflux are commonly found in obese people, but it is not clear how obesity causes these symptoms. The purpose of this study was to analyze
Clin Gastroenterology H: Vitamin D levels drop after Crohn's disease diagnosis
Time of Update: 2020-07-10
However, in the samples after diagnosis, the researchers found a negative correlation between cDs and the highest triple digits of vitamin D (P -0.01; advantage ratio 0.51; 95% CI was 0.30-0.86).
Clin Gastroenterology H: Comparison of pregnancy times in women with and without inflammatory bowel disease
Time of Update: 2020-07-10
Compared to non-IBD pregnancies, the relative risk ratio of correction for women who underwent CD surgery before conception was 2.54 (95% CI, 1.39-4.65) at the time of pregnancy.
Clin Gastroenterology H: Reduced physical labor capacity and iron utilization in adolescents with non-alcoholic fatty liver disease
Time of Update: 2020-07-10
The lower PWC for adolescents with NAFLD was associated with lower ferritin saturation (0.012 W/kg per unit, P .007) and adolescents without NAFLD were not associated (decrease of 0.001 W/ kg, P s .40).
Clin? Gastroenterology H: Trends in New Diabetes and Risk of Pancreatic Cancer in People
Time of Update: 2020-07-10
For patients with recent diagnosis diabetes (1 year or less), the researchers compared vertical changes in glucose, HbA1c and weight between diabetes and non-pancreatic cancer patients in the three years between diagnosis and diagnosis.
Clin Gastroenterology H: Alcohol intake in non-alcoholic fatty liver patients is associated with liver fat degeneration
Time of Update: 2020-07-10
conclusions in this study researchers observed a link between alcohol consumption and non-alcoholic fatty liver disease.
Clin Gastroenterology H: Early colonoscopy does not improve prognosis in patients with lower digestive tract bleeding
Time of Update: 2020-07-10
This study systematically evaluated randomized trials to determine the best time for colonoscopy in acute LGIB inpatients.
